A retrospective pharmacovigilance study revealed that adalimumab was the only TNF-α inhibitor associated with an elevated risk of cardiovascular adverse events (myocardial infarction, arterial thrombosis), whereas the other four TNF-α inhibitors did not show any increased risk [53]. The gene discussed is TNF; the disease is Arterial thrombosis.